We earn the trust of our LPs, stand with entrepreneurs, and keep ourselves accountable every step of the way.
We keep doing the right thing - long term. We push to stay sharp and create value that lasts.
We learn, adapt, and grow. We don’t chase trends - we build the edge that sets us apart.
LongRiver portfolio company, Ouro Medicines, has entered into a definitive agreement to be acquired by Gilead Sciences.
On September 8, LongRiver Investments hosted its 2025 Annual Conference in Liangxi, Wuxi, under the theme “Sail Beyond, Quest Profound.”
LongRiver Investments is thrilled to announce the launch of its UK office, based in Cambridge, marking a significant milestone in the firm’s continued commitment to investing in biotechnology and deep technology across the Cambridge–Oxford–London corridor and throughout Europe.
On September 3rd, LongRiver Investments hosted its highly anticipated 2024 Annual General Meeting in Hong Kong.
